CBL-A1

CBL-A1 is an investigational injectable drug evaluated as a comparator in clinical trials for subcutaneous fat reduction. It has been studied alongside CBL-514 and CBL-A2 in randomized, placebo-controlled Phase 2b studies targeting adults with moderate or severe abdominal fat. In these studies, participants received up to four subcutaneous injections of the allocated study drug at three-week intervals. While detailed mechanistic information about CBL-A1 is not provided in public sources, it serves as an active comparator to the lead candidate CBL-514, which acts by inducing adipocyte apoptosis and lipolysis. The primary indication under investigation for CBL-A1 is non-invasive reduction of subcutaneous abdominal fat[1][2].